Form 8-K - Current report:
SEC Accession No. 0001213900-25-000418
Filing Date
2025-01-02
Accepted
2025-01-02 16:54:33
Documents
15
Period of Report
2024-12-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0226688-8k_nkgen.htm   iXBRL 8-K 34060
2 SEVENTH AMENDMENT TO FORWARD PURCHASE AGREEMENT, DATED AS OF DECEMBER 31, 2024, ea022668801ex10-1_nkgen.htm EX-10.1 13930
  Complete submission text file 0001213900-25-000418.txt   273315

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE nkgn-20241231.xsd EX-101.SCH 3882
4 XBRL DEFINITION FILE nkgn-20241231_def.xml EX-101.DEF 26779
5 XBRL LABEL FILE nkgn-20241231_lab.xml EX-101.LAB 37008
6 XBRL PRESENTATION FILE nkgn-20241231_pre.xml EX-101.PRE 25403
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0226688-8k_nkgen_htm.xml XML 6001
Mailing Address 3001 DAIMLER ST, SANTA ANA CA 92705
Business Address 3001 DAIMLER ST, SANTA ANA CA 92705 (949) 396-6830
NKGen Biotech, Inc. (Filer) CIK: 0001845459 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40427 | Film No.: 25502728
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)